To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Editorial Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension Management – A New Approach For a Rare Disease Jean-Luc Vachiery Pulmonary Vascular Diseases Clinic, Department of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium P ulmonary Arterial Hypertension is a rare, deadly and incurable condition for which management guidelines have recently been revised. Important and remarkable changes include a new strategy-oriented treatment algorithm, based on a risk-stratification approach. Combination therapy is recommended as soon as diagnosis is established for all patients, with a parenteral prostacyclin for the most severe cases. The uncommon nature of the disease and the management complexity require that care is delivered by expert specialised centers. Keywords Pulmonary arterial hypertension, guidelines, combination therapy, expert, risk stratification, pulmonary hypertension Disclosure: Jean-Luc Vachiery has nothing to disclose in relation to this paper. This article is a short opinion piece and has not been submitted to external peer reviewers. No funding was received for the publication of this article. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Pulmonary arterial hypertension (PAH) is a rare, deadly and incurable condition. 1 With a five-year survival rate below 60%, the outcome of this disease is not any better than that of many cancers. 1,2 However, numerous treatment options are currently available: more than 20 randomised controlled trials (RCTs) have been conducted over the past 10 years, allowing for the approval of 10 PAH-specific drugs by regulatory agencies worldwide. 1,2 In addition, the recent completion of four event-driven RCTs geared the management of PAH towards a new era. 3–6 PAH is therefore one of the very few rare conditions for which international practice guidelines were established more than 10 years ago. In 2015, the European Society of Cardiology and the European Respiratory Society (together with the International Society for Heart and Lung Transplantation) joined forces to revise previous guidelines and present the most recent standards for the management of PAH. 1 Three major changes warrant special attention. Received: 8 July 2016 Published Online: 12 August 2016 Citation: European Respiratory & Pulmonary Diseases, 2016;2(2):50–1 Corresponding Author: Jean-Luc Vachiery, Department of Cardiology, CUB – Hopital Erasme, 808 Route de Lennik 1070 – Brussels, Belgium. E: The first change is risk stratification, which has been proposed as the gatekeeper to the treatment algorithm. Such an essential exercise requires careful assessment and allows clinicians to stratify individual patients based on three factors: 1. Clinical, which includes New York Heart Association (NYHA) functional class and signs of right heart failure; 2. Exercise capacity, using either the six-minute walking distance (6MWD) test or the more sophisticated cardiopulmonary exercise test; and 3. Right ventricular function, with special attention to invasive haemodynamics. Up to 14 meaningful, easily retrievable variables are considered in this analysis to establish whether the one-year mortality risk is low (<5%), intermediate (5–10%) or high (>10%). This evaluation is recommended both at baseline (in treatment-naïve patients) and during follow up (to demonstrate inadequate clinical response). The second change is a new strategy-oriented treatment algorithm, moving away from a more traditional drug-driven standard. This algorithm reflects an important paradigm shift in the management of PAH. There is indeed little question that combination therapy is effective in PAH. Recently published RCTs demonstrate that adding a second agent improves exercise capacity (by 6MWD) in patients receiving riociguat 7 (a soluble guanalyte cyclase stimulator, GCs) or macitentan 3 (an endothelin receptor antagonist [ERA]), and delays clinical worsening in patients receiving macitentan 3 or selexipag 5 (a prostacyclin receptor agonist). In newly diagnosed patients, combination therapy with ambrisentan (an ERA) and tadalafil (a phosphodiesterase type 5 inhibitor, PDE5i) delays time to clinical worsening compared with monotherapy with either compound. 4 Finally, patients presenting severe, high-risk PAH appear to benefit from a combination of parenteral prostacyclin and oral agents. 1 Therefore, a sound strategy would favour initial combination therapy in patients with intermediate or high risk, the latter including a parenteral prostacyclin. 50 TOU C H ME D ICA L ME D IA